Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory DOI Creative Commons
Jie Bai, Asako Chiba,

Goh Murayama

et al.

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: Nov. 27, 2022

Abstract Longitudinal studies have revealed large interindividual differences in antibody responses induced by SARS-CoV-2 mRNA vaccines. Thus, we performed a comprehensive analysis of adaptive immune three doses the BNT162b2 The spike-specific CD4 + T cells, CD8 cells and serum IgG, neutralization capacities two vaccines declined 6 months later. 3 rd dose increased spike IgG neutralizing against wild-type Omicron spikes to higher levels than 2 nd dose, this was supported memory B cell responses, which gradually after were further enhanced dose. moderately frequencies but remained unchanged. reactive 1.3-fold fewer those spike. early responsiveness T, circulating follicular helper peripheral correlated with booster vaccination, also associated responses. These findings highlight importance evaluating cellular optimize future vaccine strategies.

Language: Английский

Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination DOI Creative Commons

Ángela Sánchez‐Simarro,

Daniel Fernández‐Soto, Brayan Grau

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: May 24, 2024

The immune effector mechanisms involved in protecting against severe COVID-19 infection elderly nursing home residents following vaccination or natural are not well understood. Here, we measured SARS-CoV-2 Spike (S)-directed functional antibody responses, including neutralizing antibodies (NtAb) and Fc-mediated NK cell activity (degranulation IFNγ production), the Wuhan-Hu-1, BA.4/5 (for NtAb), Omicron XBB.1.5 variants (n = 39; median age, 91 years) before a third (pre- post-3D) fourth post-4D) mRNA vaccine dose. Both 3D 4D boosted NtAb levels both (sub)variants. Likewise, increased ability of sera to trigger LAMP1- IFNγ-producing cells, particular XBB.1.5. In contrast titres, frequencies cells activated by binding Wuhan-Hu-1 S were comparable at all testing times. Stronger responses observed vaccine-experienced participants compared vaccine-naïve some These findings can contribute identifying reliable correlate protection inform future strategies this population group.

Language: Английский

Citations

1
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial DOI Open Access
Gilda Lemos,

Yinet Barrese-Pérez,

Yahima Chacón-Quintero

et al.

Published: June 11, 2024

A phase 1-2, prospective, multicenter, randomized, open-label clinical trial (Code RPCEC00000382, https://rpcec.sld.cu/trials/RPCEC00000382-En/), with parallel groups, involving 1161 participants was designed to assess safety and immunogenicity of two Cuban COVID-19 vaccines (Mambisa Abdala) in boosting immunity convalescent adults after receiving one dose either vaccine. The main outcome severe vaccination adverse events occurring <5% vaccinees. Main success endpoints were ≥4-fold anti-RBD IgG seroconversion or ≥20% increase ACE2-RBD inhibitory antibodies >55% vaccinees Phase 1 >70% 2. Neutralizing antibody titers against SARS-CoV-2 variants evaluated. Both safe; no deaths occurred. Mild intensity the most frequent (>73%); headache predominated for both vaccines. responders 83.3% (p = 0.0018) Abdala. Mambisa showed similar results. 2 88.6% Abdala <0.0001) 74.2% 0.0412). In phases, titers, inhibition percentages neutralizing increased significantly booster dose. safe their surpassed study endpoints.

Language: Английский

Citations

1
Safety, Immunogenicity, and Effectiveness of Chinese-Made COVID-19 Vaccines in the Real World: An Interim Report of a Living Systematic Review DOI Creative Commons
Yangyang Qi, Hui Zheng, Jinxia Wang

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 781 - 781

Published: July 16, 2024

Background: Several COVID-19 vaccines were developed and approved in China. Of these, the BIBB-CorV CoronaVac inactivated whole-virion widely distributed China developing countries. However, performance of two real world has not been summarized. Methods: A living systematic review based on findings from ongoing post-licensure studies was conducted, applying standardized algorithms. Articles published between 1 May 2020 31 2022 English Chinese searched for Medline, Embase, WanFang Data, medRxiv, bioRxiv, arXiv, SSRN, Research Square, using SARS-CoV-2, COVID-19, vaccine as MeSH terms. Studies with estimates safety, immunogenicity, effectiveness receiving or that met predefined screening criteria underwent a full-text review. The Joanna Briggs Institute’s Critical Appraisal Checklist Cochrane risk bias used assessment quality. random-effects meta-regression model applied to identify potential impact factors vaccines’ effectiveness. Results: In total, 32578 articles identified, 770 Eventually, 213 included. pooled occurrence solicited unsolicited adverse events after any dose either varied 10% 40%. top five commonly reported rare immunization stress-related responses (211 cases, 50.0%), cutaneous (43 10.2%), acute neurological syndrome (39 9.2%), anaphylaxis (17 4.0%), stroke (16 3.8%). majority (83.3%) recovered relieved within several days. peak neutralization titers against ancestral strain found month completion primary series vaccine, GMT (geometric mean titer) 43.7 (95% CI: 23.2–82.4), followed by dramatic decrease 3 months. At Month 12, 4.1 3.8–4.4). Homologous boosting could restore humoral immunity, while heterologous elicited around sixfold higher comparison homologous boosting. death severe disease 85% both shortly series. protection did decline, decreased ~75%. Conclusions: Both BIBP-CorV are safe. Sustained determined 12 months series, although slightly over time. booster strengthen waning effectiveness; however, duration incremental additional benefit provided need be studied.

Language: Английский

Citations

1
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial DOI Creative Commons
Gilda Lemos,

Yinet Barrese-Pérez,

Yahima Chacón-Quintero

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(9), P. 1001 - 1001

Published: Sept. 1, 2024

A phase 1–2, prospective, multicenter, randomized, open-label clinical trial (Code RPCEC00000382), with parallel groups, involving 1161 participants, was designed to assess the safety and immunogenicity of two Cuban COVID-19 vaccines (Mambisa Abdala) in boosting immunity convalescent adults after receiving one dose either vaccine. The main outcome severe vaccination adverse events occurring <5% vaccinees. Main success endpoints were a ≥4-fold anti-RBD IgG seroconversion or ≥20% increase ACE2-RBD inhibitory antibodies >55% vaccinees Phase 1 >70% 2. Neutralizing antibody titers against SARS-CoV-2 variants evaluated. Both safe—no deaths occurred. Mild intensity most frequent (>73%); headaches predominated for both vaccines. responders 83.3% (p = 0.0018) Abdala. Mambisa showed similar results. 2 88.6% Abdala < 0.0001) 74.2% 0.0412). In phases, titers, inhibition percentages neutralizing increased significantly booster dose. safe their surpassed study endpoints.

Language: Английский

Citations

1
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory DOI Creative Commons
Jie Bai, Asako Chiba,

Goh Murayama

et al.

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: Nov. 27, 2022

Abstract Longitudinal studies have revealed large interindividual differences in antibody responses induced by SARS-CoV-2 mRNA vaccines. Thus, we performed a comprehensive analysis of adaptive immune three doses the BNT162b2 The spike-specific CD4 + T cells, CD8 cells and serum IgG, neutralization capacities two vaccines declined 6 months later. 3 rd dose increased spike IgG neutralizing against wild-type Omicron spikes to higher levels than 2 nd dose, this was supported memory B cell responses, which gradually after were further enhanced dose. moderately frequencies but remained unchanged. reactive 1.3-fold fewer those spike. early responsiveness T, circulating follicular helper peripheral correlated with booster vaccination, also associated responses. These findings highlight importance evaluating cellular optimize future vaccine strategies.

Language: Английский

Citations

7